• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Acadia Pharmaceuticals Set to Join S&P SmallCap 600

    12/30/24 5:37:00 PM ET
    $ACAD
    $IBTX
    $SPGI
    $SSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $ACAD alert in real time by email

    NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

    Following is a summary of the change that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    Jan 3, 2025

    S&P SmallCap 600

    Addition

    Acadia Pharmaceuticals

    ACAD

    Health Care

    Jan 3, 2025

    S&P SmallCap 600

    Deletion

    Independent Bank Group

    IBTX

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com 

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com. 

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

    SOURCE S&P Dow Jones Indices

    Get the next $ACAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAD
    $IBTX
    $SPGI
    $SSB

    CompanyDatePrice TargetRatingAnalyst
    SouthState Corporation
    $SSB
    5/21/2025$110.00Buy
    Jefferies
    ACADIA Pharmaceuticals Inc.
    $ACAD
    5/21/2025$35.00Hold → Buy
    Deutsche Bank
    SouthState Corporation
    $SSB
    5/13/2025$106.00Buy
    Truist
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    SouthState Corporation
    $SSB
    4/2/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    SouthState Corporation
    $SSB
    4/1/2025$120.00Overweight
    Barclays
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/11/2025$22.00Hold
    Deutsche Bank
    More analyst ratings

    $ACAD
    $IBTX
    $SPGI
    $SSB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

      9/18/23 10:47:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

      9/18/23 10:40:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DAYBUE issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

      3/13/23 10:37:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care